Advertisement

Topics

These highlights do not include all the information needed to use AZELASTINE HYDROCHLORIDE NASAL SPRAY safely and effectively. See full prescribing information for AZELASTINE HYDROCHLORIDE NASAL SPRAY. AZELASTINE hydrochloride nasal spray, for intranasal | Azelastine Hydrochloride [Amneal Pharmaceuticals LLC] | BioPortfolio

12:41 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Azelastine HCl nasal spray, 0.15% is indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 6 years of age and older and perennial allergic rhinitis in patients 6 years of age and older.

Children 6 to 11 years of age: Azelastine HCl nasal spray, 0.15%, 1 spray per nostril twice daily.

Adults and adolescents 12 years of age and older: Azelastine HCl nasal spray, 0.15%, 1 or 2 sprays per nostril twice daily. Azelastine HCl nasal spray, 0.15% may also be administered as 2 sprays per nostril once daily.

Children 6 to 11 years of age: Azelastine HCl nasal spray, 0.15%, 1 spray per nostril twice daily.

Adults and adolescents 12 years of age and older: Azelastine HCl nasal spray, 0.15%, 2 sprays per nostril twice daily.

Administer azelastine HCl nasal spray, 0.15% by the intranasal route only.

Priming: Prime azelastine HCl nasal spray, 0.15% before initial use by releasing 6 sprays or until a fine mist appears. When azelastine HCl nasal spray, 0.15% has not been used for 3 or more days, reprime with 2 sprays or until a fine mist appears.

Avoid spraying azelastine HCl nasal spray, 0.15% into the eyes.

Azelastine HCl nasal spray, 0.15% is a nasal spray solution available in one dosage strength:

None.

In clinical trials, the occurrence of somnolence has been reported in some patients taking azelastine HCl nasal spray, 0.15% [see Adverse Reactions (6.1)]. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination such as operating machinery or driving a motor vehicle after administration of azelastine HCl nasal spray, 0.15%. Concurrent use of azelastine HCl nasal spray, 0.15% with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur [see Drug Interactions (7.1)].

Use of azelastine HCl nasal spray, 0.15% has been associated with somnolence [see Warnings and Precautions (5.1)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.

Children 6 to 11 years of age

 

In a 4 week clinical trial, 489 patients ages 6 to 11 years with perennial allergic rhinitis, with or without concomitant seasonal allergic rhinitis, were treated with either azelastine HCl nasal spray, 0.1%, azelastine HCl nasal spray, 0.15% or placebo, one spray per nostril twice daily. Overall, adverse events were similar in the azelastine HCl nasal spray, 0.15% group (24%), azelastine HCl nasal spray, 0.1% group (26%) and the placebo group (24%). Overall, less than 1% of the combined azelastine HCl nasal spray groups discontinued due to adverse events.

Table 2 contains adverse reactions reported with frequencies greater than or equal to 2% and more frequently than placebo in children 6 to 11 years of age treated with azelastine HCl nasal spray, 0.1% OR azelastine HCl nasal spray, 0.15% in the controlled trial described above.

Table 2. Adverse Reactions Reported in ≥2% Incidence in a Placebo-Controlled Trial of 4 Weeks’ Duration with Azelastine HCl Nasal Spray, 0.1% or Azelastine HCl Nasal Spray, 0.15% in Children 6 to 11 Years of Age with Perennial Allergic Rhinitis

Children 6 months to 5 years

In a 4 week clinical trial, 191 patients ages 6 months to 5 years with either seasonal and/or perennial allergic rhinitis were treated with either azelastine HCl nasal spray, 0.1% or azelastine HCl nasal spray, 0.15% one spray per nostril twice daily. The most frequently (≥2%) reported adverse reactions were pyrexia, cough, epistaxis, sneezing, dysgeusia, rhinalgia, upper respiratory infection, vomiting, otitis media, contact dermatitis, and oropharyngeal pain. Overall, adverse events were slightly higher in the azelastine HCl nasal spray, 0.15% group (28%) compared to azelastine HCl nasal spray, 0.1% group (21%). Focused nasal examinations were performed and showed no incidence of nasal mucosal ulceration at any time point during the study. No patients had reports of nasal septal perforation. Overall, less than 3% of the combined azelastine HCl nasal spray groups discontinued due to adverse events.

Azelastine HCl nasal spray, 0.15%

The safety data described below reflect exposure to azelastine HCl nasal spray, 0.15% in 2114 patients (6 months of age and older) with seasonal or perennial allergic rhinitis from 10 clinical trials of 2 weeks to 12 months duration. In 8 double-blind, placebo-controlled clinical trials of 2 to 4 weeks duration, 1703 patients (646 males and 1059 females) with seasonal or perennial allergic rhinitis were treated with azelastine HCl nasal spray, 0.15% one or two sprays per nostril once or twice daily. In the 12 month open-label, active-controlled clinical trial, 466 patients (156 males and 310 females) with perennial allergic rhinitis were treated with azelastine HCl nasal spray, 0.15% two sprays per nostril twice daily. Of these 466 patients, 152 had participated in the 4-week placebo-controlled perennial allergic rhinitis clinical trials. In a 4-week, double-blind, placebo-controlled clinical trial, 161 patients (87 males and 74 females) ages 6 to 11 years of age with perennial allergic rhinitis, with or without concomitant seasonal allergic rhinitis, were treated with azelastine HCl nasal spray, 0.15% one spray per nostril twice daily. In a 4-week clinical trial, 95 patients (59 males and 36 females) ages 6 months to 5 years of age with seasonal and/or perennial allergic rhinitis were treated with azelastine HCl nasal spray, 0.15% one spray per nostril twice daily. The racial distribution for the 10 clinical trials was 79% white, 14% black, 2% Asian, and 5% other.

Adults and Adolescents 12 Years of Age and Older

In the 7 placebo controlled clinical trials of 2 to 4 week duration, 2343 patients with seasonal allergic rhinitis and 540 patients with perennial allergic rhinitis were treated with two sprays per nostril of either azelastine HCl nasal spray, 0.15% or placebo once or twice daily. Overall, adverse reactions were more common in the azelastine HCl nasal spray, 0.15% treatment groups (16 to 31%) than in the placebo groups (11 to 24%). Overall, less than 2% of patients discontinued due to adverse reactions and withdrawal due to adverse reactions was similar among the treatment groups.

Table 3 contains adverse reactions reported with frequencies greater than or equal to 2% and more frequently than placebo in patients treated with azelastine HCl nasal spray, 0.15% in the seasonal and perennial allergic rhinitis controlled clinical trials.

Table 3. Adverse Reactions with ≥2% Incidence in Placebo-Controlled Trials of 2 to 4 Weeks’ Duration with Azelastine HCl Nasal Spray, 0.15% in Adult and Adolescent Patients With Seasonal or Perennial Allergic Rhinitis

In the above trials, somnolence was reported in <1% of patients treated with azelastine HCl nasal spray, 0.15% (11 of 1544) or vehicle placebo (1 of 1339).

Long-Term (12 Month) Safety Trial

In the 12 month, open-label, active-controlled, long-term safety trial, 466 patients (12 years of age and older) with perennial allergic rhinitis were treated with azelastine HCl nasal spray, 0.15% two sprays per nostril twice daily and 237 patients were treated with mometasone nasal spray two sprays per nostril once daily. The most frequently reported adverse reactions (>5%) with azelastine HCl nasal spray, 0.15% were bitter taste, headache, sinusitis, and epistaxis. Focused nasal examinations were performed and no nasal ulcerations or septal perforations were observed. In each treatment group, approximately 3% of patients had mild epistaxis. No patients had reports of severe epistaxis. Fifty-four patients (12%) treated with azelastine HCl nasal spray, 0.15% and 17 patients (7%) treated with mometasone nasal spray discontinued from the trial due to adverse events.

1 spray twice daily
Azelastine HCl Nasal Spray, 0.1% (N=166) Azelastine HCl Nasal Spray, 0.15% (N=161) Vehicle Placebo (N=162)
Epistaxis 8 (5%) 7 (4%) 5 (3%)
Nasal Discomfort 1 (<1%) 7 (4%) 0 (0%)
Dysgeusia 4 (2%) 6 (4%) 1 (<1%)
Upper respiratory infection 4 (2%) 4 (3%) 3 (2%)
Sneezing 3 (2%) 4 (3%) 2 (1%)
2 sprays twice daily 2 sprays once daily
Azelastine HCl Nasal Spray, 0.15% (N=523) Vehicle Placebo (N=523) Azelastine HCl Nasal Spray, 0.15% (N=1021) Vehicle Placebo (N=816)
Bitter Taste 31 (6%) 5 (1%) 38 (4%) 2 (<1%)
Nasal Discomfort 18 (3%) 12 (2%) 37 (4%) 7 (1%)
Epistaxis 5 (1%) 7 (1%) 21 (2%) 14 (2%)
Sneezing 9 (2%) 1 (<1%) 14 (1%) 0 (0%)

During the post approval use of azelastine HCl nasal spray, 0.15%, the following adverse reactions have been identified. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions reported include: abdominal pain, atrial fibrillation, blurred vision, chest pain, confusion, disturbance or loss of sense of smell and/or taste, dizziness, dyspnea, facial swelling, hypertension, involuntary muscle contractions, nasal burning, nausea, nervousness, palpitations, paresthesia, parosmia, pruritus, rash, sneezing, insomnia, sweet taste, tachycardia, and throat irritation.

Additionally, the following adverse reactions have been identified during the post approval use of the Astelin brand of azelastine HCl 0.1% nasal spray (total daily dose 0.55 mg to 1.1 mg). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions reported include the following: anaphylactoid reaction, application site irritation, facial edema, paroxysmal sneezing, tolerance, urinary retention, and xerophthalmia.

Concurrent use of azelastine HCl nasal spray, 0.15% with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur [see Warnings and Precautions (5.1)].

Interaction studies investigating the cardiac effects, as measured by the corrected QT interval (QTc), of concomitantly administered oral azelastine HCl and erythromycin or ketoconazole were conducted. Oral erythromycin (500 mg three times daily for 7 days) had no effect on azelastine pharmacokinetics or QTc based on analyses of serial electrocardiograms. Ketoconazole (200 mg twice daily for 7 days) interfered with the measurement of azelastine plasma concentrations on the analytic HPLC; however, no effects on QTc were observed [see Clinical Pharmacology (12.2) and (12.3) ].

Cimetidine (400 mg twice daily) increased the mean C and AUC of orally administered azelastine HCl (4 mg twice daily) by approximately 65% [see Clinical Pharmacology (12.3) ].

Pregnancy Category C: There are no adequate and well-controlled clinical trials in pregnant women. Azelastine HCl has been shown to cause developmental toxicity in mice, rats, and rabbits. Azelastine HCl nasal spray, 0.15% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Teratogenic Effects: In mice, azelastine HCl caused embryo-fetal death, malformations (cleft palate; short or absent tail; fused, absent or branched ribs), delayed ossification, and decreased fetal weight at approximately 170 times the maximum recommended human daily intranasal dose (MRHDID) in adults (on a mg/m basis at a maternal oral dose of 68.6 mg/kg/day which also caused maternal toxicity as evidenced by decreased body weight). Neither fetal nor maternal effects occurred in mice at approximately 7 times the MRHDID in adults (on a mg/m basis at a maternal oral dose of 3 mg/kg/day).

In rats, azelastine HCl caused malformations (oligo- and brachydactylia), delayed ossification and skeletal variations, in the absence of maternal toxicity, at approximately 150 times the MRHDID in adults (on a mg/m basis at a maternal oral dose of 30 mg/kg/day). Azelastine HCl caused embryo-fetal death and decreased fetal weight and severe maternal toxicity at approximately 340 times the MRHDID (on a mg/m basis at a maternal oral dose of 68.6 mg/kg/day). Neither fetal nor maternal effects occurred at approximately 15 times the MRHDID (on a mg/m basis at a maternal oral dose of 2 mg/kg/day).

In rabbits, azelastine HCl caused abortion, delayed ossification and decreased fetal weight and severe maternal toxicity at approximately 300 times the MRHDID in adults (on a mg/m basis at a maternal oral dose of 30 mg/kg/day). Neither fetal nor maternal effects occurred at approximately 3 times the MRHDID (on a mg/m basis at a maternal oral dose of 0.3 mg/kg/day).

It is not known whether azelastine HCl is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azelastine HCl nasal spray, 0.15% is administered to a nursing woman.

The safety and effectiveness of azelastine HCl nasal spray, 0.15% have been established for seasonal allergic rhinitis in pediatric patients 6 to 17 years of age and perennial allergic rhinitis in pediatric patients 6 to 17 years of age [see Clinical Studies (14)]. The safety and effectiveness of azelastine HCl nasal spray, 0.15% in pediatric patients below 6 years of age have not been established.

Clinical trials of azelastine HCl nasal spray, 0.15% did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

There have been no reported overdosages with azelastine HCl nasal spray, 0.15%. Acute overdosage by adults with this dosage form is unlikely to result in clinically significant adverse events, other than increased somnolence, since one 30 mL bottle of azelastine HCl nasal spray, 0.15% contains up to 45 mg of azelastine HCl. Clinical trials in adults with single doses of the oral formulation of azelastine HCl (up to 16 mg) have not resulted in increased incidence of serious adverse events. General supportive measures should be employed if overdosage occurs. There is no known antidote to azelastine HCl nasal spray, 0.15%. Oral ingestion of antihistamines has the potential to cause serious adverse effects in children. Accordingly, azelastine HCl nasal spray, 0.15% should be kept out of the reach of children.

Azelastine HCl nasal spray, 0.15% is an antihistamine (H receptor antagonist) formulated as a metered-spray solution for intranasal administration.

Azelastine HCl, USP occurs as a white, almost odorless, crystalline powder with a bitter taste. It has a molecular weight of 418.36. It is sparingly soluble in water, methanol, and propylene glycol and slightly soluble in ethanol, octanol, and glycerine. It has a melting point of about 225°C and the pH of a saturated solution is between 5.0 and 5.4. Its chemical name is (±)-1-(2H)-phthalazinone,4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride. Its molecular formula is CHClNO•HCl with the following chemical structure:

Azelastine HCl nasal spray, 0.15% contains 0.15% azelastine HCl, USP in an isotonic aqueous solution containing benzalkonium chloride (125 mcg/mL), edetate disodium, hypromellose, purified water, sodium citrate, sorbitol solution and sucralose. Hydrochloric acid or sodium hydroxide may be added for adjustment of pH (pH 6.4).

After priming [see Dosage and Administration (2.3)], each metered spray delivers a 0.137 mL mean volume containing 205.5 mcg of azelastine HCl, USP (equivalent to 187.6 mcg of azelastine base). The 30 mL (net weight 30 gm of solution) bottle provides 200 metered sprays.

Azelastine HCl, a phthalazinone derivative, exhibits histamine H-receptor antagonist activity in isolated tissues, animal models, and humans. Azelastine HCl nasal spray, 0.15% is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in vitro studies. The major metabolite, desmethylazelastine, also possesses H-receptor antagonist activity.

Cardiac Effects:

In a placebo-controlled trial (95 patients with allergic rhinitis), there was no evidence of an effect of azelastine HCl nasal spray (2 sprays per nostril twice daily for 56 days) on cardiac repolarization as represented by the corrected QT interval (QTc) of the electrocardiogram. Following multiple dose oral administration of azelastine 4 mg or 8 mg twice daily, the mean change in QTc was 7.2 msec and 3.6 msec, respectively.

Interaction studies investigating the cardiac repolarization effects of concomitantly administered oral azelastine HCl and erythromycin or ketoconazole were conducted. Oral erythromycin had no effect on azelastine pharmacokinetics or QTc based on analysis of serial electrocardiograms. Ketoconazole interfered with the measurement of azelastine plasma levels; however, no effects on QTc were observed [see Drug Interactions (7.2)].

Absorption:

After intranasal administration of 2 sprays per nostril (822 mcg total dose) of azelastine HCl nasal spray, 0.15%, the mean azelastine peak plasma concentration (C) is 409 pg/mL, the mean extent of systemic exposure (AUC) is 9312 pg•hr/mL and the median time to reach C (t) is 4 hours. The systemic bioavailability of azelastine HCl is approximately 40% after intranasal administration.

Distribution:

Based on intravenous and oral administration, the steady-state volume of distribution of azelastine is 14.5 L/kg. In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.

Metabolism:

Azelastine is oxidatively metabolized to the principal active metabolite, desmethylazelastine, by the cytochrome P450 enzyme system. The specific P450 isoforms responsible for the biotransformation of azelastine have not been identified. After a single-dose, intranasal administration of azelastine HCl nasal spray, 0.15% (822 mcg total dose), the mean desmethylazelastine C is 38 pg/mL, the AUC is 3824 pg•hr/mL and the median t is 24 hours. After intranasal dosing of azelastine to steady-state, plasma concentrations of desmethylazelastine range from 20 to 50% of azelastine concentrations.

Elimination:

Following intranasal administration of azelastine HCl nasal spray, 0.15%, the elimination half-life of azelastine is 25 hours while that of desmethylazelastine is 57 hours. Approximately 75% of an oral dose of radiolabeled azelastine HCl was excreted in the feces with less than 10% as unchanged azelastine.

Special Populations:

Hepatic Impairment: Following oral administration, pharmacokinetic parameters were not influenced by hepatic impairment.

Renal Impairment: Based on oral, single-dose studies, renal insufficiency (creatinine clearance <50 mL/min) resulted in a 70 to 75% higher C and AUC compared to healthy subjects. Time to maximum concentration was unchanged.

Age: Following oral administration, pharmacokinetic parameters were not influenced by age.

Gender: Following oral administration, pharmacokinetic parameters were not influenced by gender.

Race: The effect of race has not been evaluated.

Drug-Drug Interactions:

Erythromycin: Co-administration of orally administered azelastine (4 mg twice daily) with erythromycin (500 mg three times daily for 7 days) resulted in C of 5.36 ± 2.6 ng/mL and AUC of 49.7 ± 24 ng•h/mL for azelastine, whereas, administration of azelastine alone resulted in C of 5.57 ± 2.7 ng/mL and AUC of 48.4 ± 24 ng•h/mL for azelastine [see Drug Interactions (7.2)].

Cimetidine and Ranitidine: In a multiple-dose, steady-state drug interaction trial in healthy subjects, cimetidine (400 mg twice daily) increased orally administered mean azelastine (4 mg twice daily) concentrations by approximately 65%. Co-administration of orally administered azelastine (4 mg twice daily) with ranitidine HCl (150 mg twice daily) resulted in C of 8.89 ± 3.28 ng/mL and AUC of 88.22 ± 40.43 ng•h/mL for azelastine, whereas, administration of azelastine alone resulted in C of 7.83 ± 4.06 ng/mL and AUC of 80.09 ± 43.55 ng•h/mL for azelastine [see Drug Interactions (7.3)].

 

Theophylline: No significant pharmacokinetic interaction was observed with the co-administration of an oral 4 mg dose of azelastine HCl twice daily and theophylline 300 mg or 400 mg twice daily.

In 2-year carcinogenicity studies in rats and mice, azelastine HCl did not show evidence of carcinogenicity at oral doses up to 30 mg/kg and 25 mg/kg, respectively. These doses were approximately 150 and 60 times the maximum recommended human daily intranasal dose [MRHDID] on a mg/m basis.

Azelastine HCl showed no genotoxic effects in the Ames test, DNA repair test, mouse lymphoma forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone marrow.

Reproduction and fertility studies in rats showed no effects on male or female fertility at oral doses up to 30 mg/kg (approximately 150 times the MRHDID in adults on a mg/m basis). At 68.6 mg/kg (approximately 340 times the MRHDID on a mg/m basis), the duration of estrous cycles was prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of corpora lutea and implantations were decreased; however, pre-implantation loss was not increased.

Azelastine HCl nasal spray, 0.15%

The efficacy and safety of azelastine HCl nasal spray, 0.15% in seasonal allergic rhinitis was evaluated in five randomized, multicenter, double-blind, placebo-controlled clinical trials in 2499 adult and adolescent patients 12 years and older with symptoms of seasonal allergic rhinitis (Trials 2, 3, 4, 5, and 6). The population of the trials was 12 to 83 years of age (64% female, 36% male; 81% white, 12% black, <2% Asian, 5% other; 23% Hispanic, 77% non-Hispanic). Assessment of efficacy was based on the rTNSS, iTNSS as described above, and other supportive secondary efficacy variables. The primary efficacy endpoint was the mean change from baseline in rTNSS over 2 weeks.

Two 2-week seasonal allergic rhinitis trials evaluated the efficacy of azelastine HCl nasal spray, 0.15% dosed at 2 sprays twice daily. The first trial (Trial 2) compared the efficacy of azelastine HCl nasal spray, 0.15% and azelastine HCl nasal spray, 0.1% to vehicle placebo. The other trial (Trial 3) compared the efficacy of azelastine HCl nasal spray, 0.15% and azelastine HCl nasal spray, 0.1% to vehicle placebo. In these two trials, azelastine HCl nasal spray, 0.15% demonstrated greater decreases in rTNSS than placebo and the differences were statistically significant (Table 4).

Three 2-week seasonal allergic rhinitis trials evaluated the efficacy of azelastine HCl nasal spray, 0.15% dosed at 2 sprays once daily compared to the vehicle placebo. Trial 4 demonstrated a greater decrease in rTNSS than placebo and the difference was statistically significant (Table 4). Trial 5 and Trial 6 were conducted in patients with Texas mountain cedar allergy. In Trial 5 and Trial 6, azelastine HCl nasal spray, 0.15% demonstrated a greater decrease in rTNSS than placebo and the differences were statistically significant (Trials 5 and 6; Table 4). Instantaneous TNSS results for the once daily dosing regimen of azelastine HCl nasal spray, 0.15% are shown in Table 5. In Trials 5 and 6, azelastine HCl nasal spray, 0.15% demonstrated a greater decrease in iTNSS than placebo and the differences were statistically significant.

Table 4. Mean Change from Baseline in Reflective TNSS over 2 Weeks* in Adults and Children ≥ 12 years with Seasonal Allergic Rhinitis

 

Table 5. Mean Change from Baseline AM Instantaneous TNSS over 2 Weeks* in Adults and Children ≥ 12 years with Seasonal Allergic Rhinitis

Azelastine HCl nasal spray, 0.15% at a dose of 1 spray twice daily was not studied. The azelastine HCl nasal spray, 0.15% 1 spray twice daily dosing regimen is supported by previous findings of efficacy for azelastine HCl nasal spray, 0.1% and a favorable comparison of azelastine HCl nasal spray, 0.15% to azelastine nasal spray 0.1% and azelastine HCl nasal spray 0.1% (Table 4).

The efficacy and safety of azelastine HCl nasal spray, 0.15% in children 6 to 11 years of age with seasonal allergic rhinitis was evaluated in a clinical study that enrolled pediatric patients with perennial allergic rhinitis, with or without concomitant seasonal allergic rhinitis (described below in Section 14.2).

Treatment (sprays per nostril) n Baseline LS Mean Change from Baseline Difference From Placebo
LS Mean 95% CI P value
Trial 2
Two sprays twice daily Azelastine HCl Nasal Spray, 0.15% 153 18.2 -4.3 -1.2 -2.1, -0.3 0.01
Azelastine HCl Nasal Spray, 0.1% 153 17.9 -3.9 -0.9 -1.8, 0.1 0.07
Vehicle Placebo 153 18.1 -3
Trial 3
Two sprays twice daily Azelastine HCl Nasal Spray, 0.15% 177 17.7 -5.1 -3 -3.9, -2.1 <0.001
Azelastine HCl Nasal Spray, 0.1% 169 18.2 -4.2 -2.1 -3.0, -1.2 <0.001
Vehicle Placebo 177 17.7 -2.1
Trial 4
Two sprays once daily Azelastine HCl Nasal Spray, 0.15% 238 17.4 -3.4 -1 -1.7, -0.3 0.008
Vehicle Placebo 242 17.4 -2.4
Trial 5
Two sprays once daily Azelastine HCl Nasal Spray, 0.15% 266 18.5 -3.3 -1.4 -2.1, -0.8 <0.001
Vehicle Placebo 266 18 -1.9
Trial 6
Two sprays once daily Azelastine HCl Nasal Spray, 0.15% 251 18.5 -3.4 -1.4 -2.1, -0.7 <0.001
Vehicle Placebo 254 18.8 -2
*Sum of AM and PM rTNSS for each day (Maximum score=24) and averaged over the 14 day treatment period
Treatment (sprays per nostril once daily) n Baseline LS Mean Change from Baseline Difference From Placebo
LS Mean 95% CI P value
Trial 4
Two sprays once daily Azelastine HCl Nasal Spray, 0.15% 238 8.1 -1.3 -0.2 -0.6, 0.1 0.15
Vehicle Placebo 242 8.3 -1.1
Trial 5
Two sprays once daily Azelastine HCl Nasal Spray, 0.15% 266 8.7 -1.4 -0.7 -1, -0.4 <0.001
Vehicle Placebo 266 8.3 -0.7
Trial 6
Two sprays once daily Azelastine HCl Nasal Spray, 0.15% 251 8.9 -1.4 -0.6 -0.9, -0.3 <0.001
Vehicle Placebo 254 8.9 -0.8
*AM iTNSS for each day (Maximum score=12) and averaged over the 14 day treatment period

A zelastine HCl nasal spray, 0.15%

The efficacy and safety of azelastine HCl nasal spray, 0.15% in perennial allergic rhinitis was evaluated in one randomized, multicenter, double-blind, placebo-controlled clinical trial in 578 adult and adolescent patients 12 years and older with symptoms of perennial allergic rhinitis. The population of the trial was 12 to 84 years of age (68% female, 32% male; 85% white, 11% black, 1% Asian, 3% other; 17% Hispanic, 83% non-Hispanic).

Assessment of efficacy was based on the 12-hour reflective total nasal symptom score (rTNSS) assessed daily in the morning and evening, the instantaneous total nasal symptom score (iTNSS), and other supportive secondary efficacy variables. The primary efficacy endpoint was the mean change from baseline rTNSS over 4 weeks. The one 4-week perennial allergic rhinitis trial evaluated the efficacy of azelastine HCl nasal spray, 0.15%, azelastine HCl nasal spray, 0.1%, and vehicle placebo dosed at 2 sprays per nostril twice daily. In this trial, azelastine HCl nasal spray, 0.15% demonstrated a greater decrease in rTNSS than placebo and the difference was statistically significant (Table 6).

Table 6. Mean Change from Baseline in Reflective TNSS over 4 Weeks* in Adults and Children ≥12 years with Perennial Allergic Rhinitis

The efficacy and safety of azelastine HCl nasal spray, 0.1% and azelastine HCl nasal spray, 0.15% in pediatric patients 6 to 11 years of age with perennial allergic rhinitis, with or without concomitant seasonal allergic rhinitis, was evaluated in a randomized, double-blind, placebo-controlled clinical trial in 486 patients. All patients received one spray per nostril twice daily. The study population was 58% males and 42% females; 78% white, 13% black, 3% Asian, and 6% other.

Assessment of efficacy was based on the 12-hour reflective total nasal symptom score (rTNSS) assessed daily in the morning and evening. The primary efficacy endpoint was the mean change from baseline rTNSS over 4 weeks (Table 7). Both active treatments demonstrated statistically significant decreases in rTNSS compared to placebo. There was no statistically significant difference between the two active-treatment groups. There was also no difference in treatment effect between patients with perennial allergic rhinitis only compared to those with perennial allergic rhinitis and concomitant seasonal allergic rhinitis.

Table 7. Mean Change from Baseline in Reflective TNSS over 4 Weeks* in Children 6 to 11 years with Perennial Allergic Rhinitis

 

The efficacy of azelastine HCl nasal spray, 0.1% and azelastine HCl nasal spray, 0.15% in children 6 months to 5 years of age with allergic rhinitis was explored in a clinical study (described above in Section 14.1).

Treatment (sprays per nostril twice daily) n Baseline LS Mean Change from Baseline Difference From Placebo
LS Mean 95% CI P value
Two sprays twice daily Azelastine HCl Nasal Spray, 0.15% 192 15.8 -4 -0.9 -1.7, -0.1 0.03
Azelastine HCl Nasal Spray, 0.1% 194 15.5 -3.8 -0.7 -1.5, 0.1 0.08
Vehicle Placebo 192 14.7 -3.1
*Sum of AM and PM rTNSS for each day (Maximum score=24) and averaged over the 28 day treatment period
Treatment (sprays per nostril twice daily) n Baseline LS Mean Change from Baseline Difference From Placebo
LS Mean 95% CI P value
One spray twice daily Azelastine HCl Nasal Spray, 0.15% 159 16.6 -3.5 -1 -1.7, -0.3 0.005
Azelastine HCl Nasal Spray, 0.1% 166 16.4 -3.4 -0.9 -1.6, -0.2 0.015
Vehicle Placebo 161 16.1 -2.5
*Sum of AM and PM rTNSS for each day (Maximum score=24) and averaged over the 28 day treatment period

Azelastine HCl nasal spray, 0.15% is supplied as a 30 mL package (NDC 65162-706-84) delivering 200 metered sprays in a high-density polyethylene (HDPE) bottle fitted with a metered-dose spray pump unit. The spray pump unit consists of a nasal spray pump fitted with a white safety clip and a white or clear plastic dust cover. The net content of the bottle is 30 mL (net weight 30 gm of solution). The 30 mL bottle contains 45 mg (1.5 mg/mL) of azelastine HCl, USP. After priming [see Dosage and Administration (2.3)], each spray delivers a fine mist containing a mean volume of 0.137 mL solution containing 205.5 mcg of azelastine HCl, USP. The correct amount of medication in each spray cannot be assured before the initial priming and after 200 sprays for the 30 mL bottle have been used, even though the bottle is not completely empty. The bottle should be discarded after 200 sprays have been used.

Azelastine HCl nasal spray, 0.15% should not be used after the expiration date “EXP” printed on the medicine label and carton.

Storage

Store upright at controlled room temperature 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.

See FDA-approved patient labeling (Patient Information and Instructions for Use).

Activities Requiring Mental Alertness

Somnolence has been reported in some patients taking azelastine HCl nasal spray, 0.15%. Caution patients against engaging in hazardous occupations requiring complete mental alertness and motor coordination such as driving or operating machinery after administration of azelastine HCl nasal spray, 0.15% [see Warnings and Precautions (5.1)].

Concurrent Use of Alcohol and other Central Nervous System Depressants

Avoid concurrent use of azelastine HCl nasal spray, 0.15% with alcohol or other central nervous system depressants because additional reductions in alertness and additional impairment of central nervous system performance may occur [see Warnings and Precautions (5.1)].

Common Adverse Reactions

Inform patients that the treatment with azelastine HCl nasal spray, 0.15% may lead to adverse reactions, most common of which include pyrexia, dysgeusia, nasal discomfort, epistaxis, headache, sneezing, fatigue, somnolence, upper respiratory infection, cough, rhinalgia, vomiting, otitis media, contact dermatitis, and oropharyngeal pain [see Adverse Reactions (6.1)].

Priming

Instruct patients to prime the pump before initial use and when azelastine HCl nasal spray, 0.15% has not been used for 3 or more days [see Dosage and Administration (2.3)].

Keep Spray Out of Eyes

Instruct patients to avoid spraying azelastine HCl nasal spray, 0.15% into their eyes.

Keep Out of Children’s Reach

Instruct patients to keep azelastine HCl nasal spray, 0.15% out of the reach of children. If a child accidentally ingests azelastine HCl nasal spray, 0.15%, seek medical help or call a poison control center immediately.

Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807

Rev. 09-2017-00

 Azelastine (a-ZEL-uh-steen) HCl Nasal Spray, 0.15%

What is Azelastine HCl Nasal Spray, 0.15% ?

It is not known if azelastine HCl nasal spray, 0.15% is safe and effective in children under 6 years of age.

What should I tell my healthcare provider before using a zelastine HCl nasal spray, 0.15% ?

Before using a zelastine HCl nasal spray, 0.15% , tell your healthcare provider if you are:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Azelastine HCl nasal spray, 0.15% and other medicines may affect each other, causing side effects.

How should I use a zelastine HCl nasal spray, 0.15% ?

What should I avoid while using a zelastine HCl nasal spray, 0.15% ?

A zelastine HCl nasal spray, 0.15% can cause sleepiness:

What are the possible side effects of a zelastine HCl nasal spray, 0.15% ?

The most common side effects of azelastine HCl nasal spray, 0.15% include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of azelastine HCl nasal spray, 0.15%. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store a zelastine HCl nasal spray, 0.15% ?

Keep a zelastine HCl nasal spray, 0.15% and all medicines out of reach of children.

General information about the safe and effective use of a zelastine HCl nasal spray, 0.15% .

Medicines are sometimes prescribed for conditions other than those listed in a Patient Information leaflet. Do not use azelastine HCl nasal spray, 0.15% for a condition for which it was not prescribed. Do not give azelastine HCl nasal spray, 0.15% to other people, even if they have the same symptoms that you have. It may harm them.

This Patient Information leaflet summarizes the most important information about azelastine HCl nasal spray, 0.15%. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about azelastine HCl nasal spray, 0.15% that is written for health professionals.

For more information, go to www.amneal.com or call 1-877-835-5472.

What are the ingredients in a zelastine HCl nasal spray, 0.15% ?

Active ingredient: azelastine HCl, USP

Inactive ingredients: benzalkonium chloride, edetate disodium, hypromellose, purified water, sodium citrate, sorbitol and sucralose.

Hydrochloric acid or sodium hydroxide may be added for adjustment of pH (pH 6.4).

*Trademarks are the property of their respective owners.

Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807

Rev. 09-2017-00

Important: For use in your nose only.

Azelastine (a-ZEL-uh-steen) Hydrochloride Nasal Spray, 0.15%

For the correct dose of medicine:

Figure A identifies the parts of your azelastine HCl nasal spray, 0.15% pump.

 

Figure A

Before you use a zelastine HCl nasal spray, 0.15% for the first time, you will need to prime the bottle.

For use in young children: An adult should help a young child use azelastine HCl nasal spray, 0.15%. (See “Using your azelastine HCl nasal spray, 0.15%” Steps 1 through 8).

 

P riming your a zelastine HCl nasal spray, 0.15%

Remove the dust cover over the tip of the bottle and the white safety clip just under the “shoulders” of the bottle (See Figure B).

Figure B

Now your pump is primed and ready to use.

 

Figure C

 

Figure D

Step 4.              Close your other nostril with a finger. Press the pump 1 time and sniff gently at the same time, keeping your head tilted forward and down (See Figure E).

 

Figure E

Step 5.             Repeat Step 3 and Step 4 in your other nostril.

Step 6.             If your healthcare provider tells you to use 2 sprays in each nostril, repeat Steps 2 through 4 above for the second spray in each nostril.

Step 7.             Breathe in gently, and do not tilt your head back after using azelastine HCl nasal spray, 0.15%. This will help to keep the medicine from going into your throat.

Step 8.             When you finish using your azelastine HCl nasal spray, 0.15%, wipe                                   the spray tip with a clean tissue or cloth. Put the safety clip and dust cover back on the bottle.

Cleaning the Spray Tip of your A zelastine HCl Nasal Spray, 0.15%

 

 

Figure F

Figure G

 

This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.

Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807

Rev. 09-2017-00

Important: For use in your nose only.

Manufacturer

Amneal Pharmaceuticals LLC

Active Ingredients

Source

Drugs and Medications [222 Associated Drugs and Medications listed on BioPortfolio]

Azelastine hydrochloride [west-ward pharmaceuticals corp.]

These highlights do not include all the information needed to use AZELASTINE HYDROCHLORIDE NASAL SPRAY safely and effectively. See full prescribing information for AZELASTINE HYDROCHLORIDE NASAL SPRAY...

Azelastine hydrochloride [apotex corp. ]

These highlights do not include all the information needed to use AZELASTINE HYDROCHLORIDE NASAL SPRAY safely and effectively. See full prescribing information for AZELASTINE HYDROCHLORIDE NASAL SPRAY...

Azelastine hydrochloride [sun pharmaceutical industries, inc.]

These highlights do not include all the information needed to use AZELASTINE HYDROCHLORIDE NASAL SOLUTION safely and effectively. See full prescribing information for AZELASTINE HYDROCHLORIDE NASAL SO...

Azelastine hydrochloride [avkare, inc.]

Azelastine HCl Nasal Spray These highlights do not include all the information needed to use AZELASTINE HYDROCHLORIDE NASAL SOLUTION (nasal spray) safely and effectively. See full prescribing informat...

Azelastine hydrochloride [breckenridge pharmaceutical, inc.]

These highlights do not include all the information needed to use AZELASTINE HYDROCHLORIDE NASAL SOLUTION (nasal spray) safely and effectively. See full prescribing information for AZELASTINE HYDROCHL...

Clinical Trials [2181 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medica...

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

The purpose of this study is to determine if two allergy medications are more effective than placebo.

PubMed Articles [229 Associated PubMed Articles listed on BioPortfolio]

Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia.

The novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line intranasal antihistamine spray (AZE) in ...

Efficient UPLC and CE Methods for the Simultaneous Determination of Azelastine Hydrochloride and Its Genotoxic Impurity.

A novel Stability indicating UPLC and CE methods were established and validated for the determination of azelastine hydrochloride (AZL) and its genotoxic impurity, benzohydrazide (BHZ) in the presence...

Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis in rats.

Berberine hydrochloride is one the effective compound among Rhizoma Coptidis, Cortex Phellodendri, and other plants. There are several clinical functions of berberine hydrochloride including anti-infl...

In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.

A number of drug-releasing contact lenses are currently being studied to address issues inherent in eye drops as a drug delivery method. In this study, we developed epinastine hydrochloride-releasing ...

Therapeutic effect of nasal corticosteroids combined with nasal antihistamine on vasomotor rhinitis.

To observe the clinical efficacy of nasal corticosteroids combined with nasal antihistamine in the treatment of vasomotor rhinitis. One hundred and twenty vasomotor rhinitis patients were randomly di...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record